# **Supporting Information**

# Tunable tissue scaffolds fabricated by *in situ* crosslink in phase separation system

Xifeng Liu,<sup>ab</sup> Wenjian Chen,<sup>ac</sup> Carl T. Gustafson,<sup>ab</sup> A. Lee Miller II,<sup>ab</sup> Brian E. Waletzki,<sup>ab</sup> Michael J. Yaszemski,<sup>ab</sup> and Lichun Lu<sup>\*ab</sup>

<sup>a.</sup>Tissue Engineering and Biomaterials Laboratory, Departments of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. \* E-mail address: <u>Lu.Lichun@mayo.edu</u> <sup>b.</sup>Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA. <sup>c.</sup>Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

## **Supplementary Results**

#### S1. Polymer composition on scaffolds morphology



**Fig. S1** The sample images of crosslinked 3-D porous PPF-*co*-PLLA scaffolds with polymer compositions of 5, 10 and 15%.

#### S2. Gel fraction and swelling ratio of crosslinked porous scaffolds



**Fig. S2** (A) Gel fraction and (B) swelling ratio determined for the crosslinked solid substrates and porous scaffolds with polymer compositions of 9, 5 and 3%.

#### S3. Crystallization in scaffolds with varied polymer composition



**Fig. S3** DSC curves of crosslinked solid PPF-*co*-PLLA substrates and crosslinked 3-D porous PPF-*co*-PLLA scaffolds with polymer compositions of 9, 5 and 3%.

### S4. Cytotoxicity of crosslinked porous scaffolds



**Fig. S4** Cytotoxicity of crosslinked PPF-*co*-PLLA solid and porous scaffolds after 5 days co-culture with MC3T3 cells.